The bill replaces the statutory name for the program under part C of title XVIII of the Social Security Act with the “Alternative Private Health Plan” program and treats historical program names (Medicare+Choice, Medicare Advantage, MA) as references to the new name. It also directs the Secretary of HHS to manage an orderly transition in terminology and sets an explicit completion milestone for plan-year materials.
Separately, the bill amends section 1128A of the Social Security Act to impose a civil money penalty of $100,000 for each instance in which an entity advertises a Part C plan using the term “Medicare” in the plan’s title, and it folds this penalty into the existing administrative enforcement framework for 1128A penalties. The combination of a statutory rebrand plus a high per-instance penalty creates near-term compliance, marketing, and litigation questions for Medicare Advantage organizations, brokers, and CMS.
At a Glance
What It Does
It renames the Part C Medicare program as the “Alternative Private Health Plan” program, deems legacy references (including “Medicare Advantage” and “MA”) to be references to the new name, and requires HHS to transition terminology. It also adds a new civil money penalty—$100,000 per instance—against any entity that advertises a Part C plan by using the word “Medicare” in the plan’s title and subjects that penalty to the procedural provisions already in section 1128A.
Who It Affects
Primary effects fall on Medicare Advantage organizations (MAOs), plan sponsors, brokers and marketing firms that name or advertise Part C products, as well as CMS/HHS officials who must implement terminology changes and enforce the new penalty. Beneficiaries and consumer advocates are affected indirectly via changes to plan names and marketing.
Why It Matters
This is a statutory reclassification of an entire Medicare program combined with a new, high-stakes enforcement tool that directly targets plan branding. For compliance officers and in-house counsel it signals immediate rebranding, marketing audits, and legal risk; for CMS it creates a separate operational task to manage the terminology transition and enforcement.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill does two discrete things. First, it changes what the statute calls the Part C program under title XVIII: instead of “Medicare Advantage” the program will be called the “Alternative Private Health Plan” program.
The bill includes a deeming clause so that where statute, regulation, or prior law mentions “Medicare+Choice,” “Medicare Advantage,” or “MA,” those references will be treated as pointing to the new name. To limit confusion while materials are changed, HHS must manage a transition and complete it for plan-year materials beginning on or after October 15, 2023.
Second, the bill inserts a new subsection into section 1128A that makes any entity that “advertises a plan under part C” using the term “Medicare” in the plan’s title subject to a $100,000 civil money penalty for each instance of the use. The amendment explicitly applies the existing procedural provisions in 1128A (the bill references subsections (c), (g), and (h)) to these penalties, which means the administrative enforcement and appeal processes that apply to other 1128A penalties will also apply here.Taken together, the two changes alter both the statutory vocabulary that appears across law and regulation and the commercial environment for Part C plan marketing.
The deeming language aims to make the rename comprehensive for legal references; the penalty targets marketing practice rather than the content of benefits. But the text leaves open operational questions—what counts as the “title” of a plan, whether a product trade name or advertising slogan is covered, whether an employer or broker who markets an MA plan can be liable, and how the October 2023 transition date interacts with current contract and regulatory cycles.Practical consequences are immediate.
Plan sponsors and insurers will need to audit product names, member-facing materials, broker scripts, and digital advertising; update contracts that reference “Medicare Advantage”; and budget for rebranding costs. CMS must update regulations, guidance, enrollment materials, and its own communications while standing up or reallocating enforcement resources to identify and pursue violations.
Because the penalty is per instance and substantial, the provision is likely to change marketing behavior quickly and also spur legal challenges over scope and constitutionality.
The Five Things You Need to Know
The bill renames the statutory program under part C of title XVIII to the “Alternative Private Health Plan” program and treats prior names (Medicare+Choice, Medicare Advantage, MA) as references to that new name.
It directs the Secretary of HHS to manage a terminology transition and requires completion for materials for plan years beginning on or after October 15, 2023.
Section 3 adds a new civil money penalty to section 1128A imposing $100,000 for each instance an entity advertises a Part C plan using the word “Medicare” in the plan’s title.
The new penalty is subject to the existing administrative enforcement and procedure rules in section 1128A by applying subsections (c), (g), and (h) to this penalty.
The prohibition targets use of “Medicare” in plan titles in advertising—its liability language is framed against any entity that advertises a Part C plan, leaving ambiguity about sponsors vs. intermediaries who place or create ads.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title (Save Medicare Act)
Provides the bill’s short title. It has no operational effect but identifies the package for internal and external references.
Establishes the “Alternative Private Health Plan” program
Creates the new statutory name for the Part C program and states that the Alternative Private Health Plan program shall consist of the program currently codified under part C of title XVIII. This is a structural renaming that, if enacted, changes the label used in statutory text for the entire Part C framework.
Deeming clause and transition rules
Section 2(b) says any reference to the Part C program in prior law — and specific historical program names — shall be deemed references to the new name. That means statutes, regulations, and cross-references that cite Medicare Advantage (or Medicare+Choice/MA) will be read as pointing to the Alternative Private Health Plan program. Section 2(c) instructs HHS to manage an “orderly transition” of terminological use and sets a completion milestone for plan-year materials (plan years beginning on or after October 15, 2023). Practically, the deeming clause reduces the need to amend every statute and regulation line-by-line, but it also creates an administrative workstream at CMS to update regulatory text, beneficiary materials, and data systems.
Civil money penalty for using 'Medicare' in Part C plan titles
Adds a new subsection to 1128A imposing a $100,000 civil money penalty for each instance an entity advertises a Part C plan by using “Medicare” in the plan title. The amendment ties this penalty into 1128A’s existing enforcement procedures by applying subsections (c), (g), and (h) to it. For enforcement, that generally places responsibility within HHS’s administrative apparatus for assessing, collecting, and adjudicating such penalties; it also imports procedural safeguards and collection tools that already govern other 1128A penalties. However, the provision’s wording leaves open key definitional questions—what constitutes a single “instance,” who precisely counts as “an entity that advertises,” and whether the prohibition reaches names used in issuer filings, broker listings, or employer-sponsored communications.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Medicare beneficiaries seeking clarity — fewer plan titles that incorporate the federal program name could reduce confusion between Original Medicare and privately administered Part C products when plan sponsors update marketing.
- Consumer and beneficiary advocacy organizations — the statutory change and branding restriction give advocates a clear legal basis to push for more distinct labeling of private plans and to challenge misleading marketing.
- CMS/HHS policy teams — the deeming clause simplifies statutory cross-references and creates a single, modernized program name for future regulation-writing and guidance.
Who Bears the Cost
- Medicare Advantage organizations and plan sponsors — they must audit and rebrand plan titles, membership materials, contracts, and digital assets and face the risk of heavy penalties for noncompliance.
- Brokers, agents, and marketing vendors — these intermediaries will have to change sales materials, websites, and ad campaigns and may be exposed to enforcement risk depending on how 'advertises' and 'entity' are interpreted.
- CMS/HHS and OIG — the agencies will need staff time and budget to execute the transition (updating materials, guidance, and databases) and to investigate and enforce potential violations under 1128A.
- Issuers and employers administering employer-group MA plans — they may face contractual and operational disruption as plan names are changed mid-cycle, and could incur costs reissuing member notices and enrollment documents.
Key Issues
The Core Tension
The bill pits two legitimate objectives against each other: protecting beneficiaries from misleading branding that suggests a private plan is the federal Medicare program, and preserving the commercial speech and brand continuity of private plan sponsors; the chosen remedy (a blanket rename plus a steep, per-instance fine) reduces ambiguity quickly but raises questions about fairness, scope, and administrative feasibility.
The bill combines a straightforward statutory rebrand with an aggressive enforcement tool, but it leaves several operationally significant questions unresolved. The statutory language does not define “title of the plan” or “advertises,” creating real uncertainty about whether the prohibition reaches a plan’s formal legal name in a CMS filing, a marketing product name used on a website, a broker’s listing, or employer communications.
The per-instance $100,000 penalty is large enough that small definitional differences could produce very different compliance burdens and enforcement outcomes.
There is also a tension between clarity for beneficiaries and restrictions on commercial speech. Courts will likely be asked to parse whether the government’s interest in preventing confusion justifies a content-related restriction on how private entities name and market their products, particularly given the harshness of the per-instance fine.
The retroactive-seeming transition milestone (plan years beginning on or after October 15, 2023) is unusual and could complicate contract cycles and prior communications; the text does not specify remedial safe harbors for inadvertent use during the transition. Finally, updating cross-references via a deeming clause minimizes the need for statutory cleanup but may require parallel regulatory and contractual fixes—there is a material risk of operational mismatch between statutory language and field-level systems (health plan directories, enrollment files, provider contracts) while agencies and the market coordinate changes.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.